Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
4d
Clinical Trials Arena on MSNNovo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trialThe Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results